Myriad Genetics' Revenues Grow 6 Percent in Q3 | GenomeWeb

NEW YORK (GenomeWeb) – Myriad Genetics reported after the close of the market Tuesday that its fiscal third quarter revenues grew 6 percent from the previous year's third quarter, beating analysts' consensus estimate.

Myriad's total revenues for Q3 was $190.5 million, up from $180.0 million in Q3 2015, and above the consensus Wall Street estimate of $184.9 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: role for Notch signaling in congenital heart disease, sciatica risk variants, and more.

Researchers in China have used the CRISPR/Cas9 genome editing approach to alter the length of hair fibers in cashmere goats.

According to ScienceInsider, the Scripps Research Institute and the California Institute for Biomedical Research are merging.

National Cancer Institute researchers didn't report severe adverse events to Food and Drug Administration in a timely manner, the Wall Street Journal reports.

Sponsored by
Agilent Technologies

In this online seminar, speakers from the Center for Personalized Diagnostics at Penn Medicine will discuss the design and technical validation of a custom next-generation sequencing panel to detect mutations in a wide array of tumor types.